Update on 'open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder' [13]

Journal of Clinical Psychopharmacology

Volumn 20, Issue 2, 2000, Pages 285-

  Moroz, Georges ^a   Magni, Guido ^b   Fava, Maurizio ^c  

^a HOFFMANN LA ROCHE INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; TOLCAPONE;

DEPRESSION; LETTER; PARKINSON DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0034040301     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200004000-00035     Document Type: Letter

References (2)